XM does not provide services to residents of the United States of America.

Intuitive beats quarterly profit estimates on strong demand for surgical robots



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Intuitive beats quarterly profit estimates on strong demand for surgical robots</title></head><body>

Adds outlook in paragraph 6, company comments in paragraph 7, background in paragraphs 8-9

By Mariam Sunny

Oct 17 (Reuters) -Medical device maker Intuitive Surgical ISRG.O beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its surgical robots used in minimally invasive procedures, sending shares up 6% in extended trading.

The company earned $1.84 per share on an adjusted basis for the quarter ended Sept. 30, beating analysts' average estimate of $1.63, according to data compiled by LSEG.

Medical device manufacturers have been benefiting from elevated demand for non-urgent surgeries as people, especially older Americans, catch up on procedures deferred during the pandemic.

Intuitive's surgical robots, da Vinci, are widely used for a range of procedures, including weight-loss surgeries and for conditions of the digestive system, bladder and heart.

Third-quarter volume of da Vinci procedures rose about 18% from a year ago, the company said.

Intuitive expects the volume of da Vinci procedures to grow between 16% and 17% this year, compared with the prior view of 15.5% to 17%.

The forecast does not reflect the significant impact to elective procedures due to the ongoing shortage of intravenous (IV) saline fluids or other hurricane-related effects, the company said on Thursday during the earnings call.

Production at Baxter International's BAX.N North Carolina plant, which makes 60% of the United States' supply of IV fluids and some key dialysis solutions, was closed late last month due to flooding caused by Hurricane Helene.

The shortage, triggered by this hit to production, is forcing hospitals to defer elective procedures and could hurt companies that make related medical devices, according to analysts.

Intuitive Surgical posted third-quarter revenue of $2.04 billion, in line with analyst estimates.

Sales at its instruments and accessories unit, which accounts for a major chunk of the revenue, rose 18% to $1.26 billion from a year ago, compared with estimates of $1.25 billion.



Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.